Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review.
CAG regimen
Early T-cell precursor acute lymphoblastic leukemia
Hematopoietic stem cell transplantation
Venetoclax
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
04
02
2023
accepted:
26
05
2023
revised:
23
05
2023
medline:
27
9
2023
pubmed:
3
6
2023
entrez:
3
6
2023
Statut:
ppublish
Résumé
This article describes a potential treatment for early T-cell precursor acute lymphoblastic leukemia (ETP-ALL), a relatively rare and highly aggressive hematologic malignancy. A 59-year-old woman admitted to our hospital with enlarged cervical lymph nodes, weight loss, abnormal count, and morphology of peripheral blood cells was diagnosed with ETP-ALL according to morphology, immunology, cytogenetics, and molecular biology. The patient initially received two cycles of the VICP regimen, including vincristine, idarubicin, cyclophosphamide, and prednisone, and had a response with positive minimal residual disease (MRD). The patient was then given venetoclax plus the CAG regimen, including aclarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor. After one cycle, the patient achieved complete remission with negative MRD and was eligible for allogeneic hematopoietic stem cell transplantation.
Identifiants
pubmed: 37269505
doi: 10.1007/s12185-023-03623-w
pii: 10.1007/s12185-023-03623-w
doi:
Substances chimiques
Aclarubicin
74KXF8I502
venetoclax
N54AIC43PW
Granulocyte Colony-Stimulating Factor
143011-72-7
Cytarabine
04079A1RDZ
Types de publication
Review
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
483-488Subventions
Organisme : Fund of the Specific Project for the Scientific Research of Traditional Chinese Medicine in Henan Province
ID : No.2022ZY1045
Organisme : the Specific Project for the National Clinical Research Base of Traditional Chinese Medicine of Henan Provincial Health Commission
ID : 2022JDZX083
Organisme : the Fifth Batch of national research and training programs for clinical talents of traditional Chinese medicine
ID : 2022-NO.1787
Informations de copyright
© 2023. Japanese Society of Hematology.
Références
Jain N, Lamb AV, O’Brien S, Ravandi F, Konopleva M, Jabbour E, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127(15):1863–9. https://doi.org/10.1182/blood-2015-08-661702 .
doi: 10.1182/blood-2015-08-661702
pubmed: 26747249
pmcid: 4915808
Garg S, Gupta SK, Bakhshi S, Mallick S, Kumar L. ETP-ALL with aberrant B marker expression: case series and a brief review of literature. Int J Lab Hematol. 2019;41(2):e32–7. https://doi.org/10.1111/ijlh.12942 .
doi: 10.1111/ijlh.12942
pubmed: 30407727
Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157–63. https://doi.org/10.1038/nature10725 .
doi: 10.1038/nature10725
pubmed: 22237106
pmcid: 3267575
Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124(25):3738–47. https://doi.org/10.1182/blood-2014-05-574566 .
doi: 10.1182/blood-2014-05-574566
pubmed: 25301704
Mullighan CG. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice. Clin Cancer Res. 2011;17(3):396–400. https://doi.org/10.1158/1078-0432.CCR-10-1203 .
doi: 10.1158/1078-0432.CCR-10-1203
pubmed: 21149616
Girardi T, Vicente C, Cools J, De Keersmaecker K. The genetics and molecular biology of T-ALL. Blood. 2017;129(9):1113–23. https://doi.org/10.1182/blood-2016-10-706465 .
doi: 10.1182/blood-2016-10-706465
pubmed: 28115373
Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147–56. https://doi.org/10.1016/S1470-2045(08)70314-0 .
doi: 10.1016/S1470-2045(08)70314-0
pubmed: 19147408
pmcid: 2840241
Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, et al. Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study. J Clin Oncol. 2017;35(23):2683. https://doi.org/10.1200/jco.2016.71.8585 .
doi: 10.1200/jco.2016.71.8585
pubmed: 28605290
Zhang Y, Qian JJ, Zhou YL, Huang X, Li JH, Li XY, et al. Comparison of early T-cell precursor and non-ETP subtypes among 122 Chinese adults with acute lymphoblastic leukemia. Front Oncol. 2020;10:1423. https://doi.org/10.3389/fonc.2020.01423 .
doi: 10.3389/fonc.2020.01423
pubmed: 32974153
pmcid: 7473208
Meng TY, Qi JQ, Zhu YX, Xu Y, Chen F, Xue SL, et al. Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T-cell precursor acute lymphoblastic leukemia. Hematol Oncol. 2021;39(3):358–63. https://doi.org/10.1002/hon.2841 .
doi: 10.1002/hon.2841
pubmed: 33521954
Qingqing W, Chenjing Q, Feiyan Y, Linghui X. The significance of detecting minimal residual disease before transplantation in the treatment of allogeneic hematopoietic stem cell transplantation in acute T lymphocyte leukemia patients Journal of Clinical. Hematology. 2021;34(07):468–76. https://doi.org/10.13201/j.issn.1004-2806.2021.07.004 .
doi: 10.13201/j.issn.1004-2806.2021.07.004
Meng T, Yao Y, Xu Y, Xue S, Han Y, Tang X, et al. Salvage therapy with decitabine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin in patients with refractory or relapsed early T-cell precursor acute lymphoblastic leukemia. Hematol Oncol. 2020;38(5):834–7. https://doi.org/10.1002/hon.2783 .
doi: 10.1002/hon.2783
pubmed: 32710795
Yamada K, Furusawa S, Saito K, Waga K, Koike T, Arimura H, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia. 1995;9(1):10–4.
pubmed: 7531259
Wei GQ, Ni WM, Chiao JW, Cai Z, Huang H, Liu DL. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol. 2011. https://doi.org/10.1186/1756-8722-4-46 .
doi: 10.1186/1756-8722-4-46
pubmed: 22082134
pmcid: 3230125
Qu Q, Liu L, Zhang Y, Li X, Wu D. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia. Leuk Res. 2015;39(12):1353–9. https://doi.org/10.1016/j.leukres.2015.09.014 .
doi: 10.1016/j.leukres.2015.09.014
pubmed: 26432074
Zhang JY, Li L, Liu W, Jin Y, Zhao M, Zhou Y, et al. Comparison of efficacy of HCAG and CAG re-induction chemotherapy in elderly low- and intermediate-risk group patients diagnosed with acute myeloid leukemia. Clin Transl Oncol. 2021;23(1):48–57. https://doi.org/10.1007/s12094-020-02383-x .
doi: 10.1007/s12094-020-02383-x
pubmed: 32458310
Xue SL, Wu DP, Sun AN, Tang XW. CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases. Am J Hematol. 2008;83(2):167–70. https://doi.org/10.1002/ajh.21066 .
doi: 10.1002/ajh.21066
pubmed: 17874449
Qian JJ, Hu X, Wang Y, Zhang Y, Du J, Yang M, et al. CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: a retrospective, multicenter, cohort study. Cancer Med. 2020;9(15):5327–34. https://doi.org/10.1002/cam4.3079 .
doi: 10.1002/cam4.3079
pubmed: 32492289
Xue SL, Cui HX, Zou JY, Xue MX, Tang XW, Zhang YM, et al. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients. Hematol Oncol. 2013;31(4):206–12. https://doi.org/10.1002/hon.2051 .
doi: 10.1002/hon.2051
pubmed: 23616245
Liu S, Cui Q, Dai H, Song B, Cui W, Xue S, et al. Early T-cell precursor acute lymphoblastic leukemia and T/myeloid mixed phenotype acute leukemia possess overlapping characteristics and both benefit from CAG-like regimens and allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2021;27(6):481.e1-e7. https://doi.org/10.1016/j.jtct.2021.02.032 .
doi: 10.1016/j.jtct.2021.02.032
Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia. 1990;4(12):826–34.
pubmed: 2243506
Te Boekhorst PA, Löwenberg B, Vlastuin M, Sonneveld P. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia. 1993;7(8):1191–8.
Bai A, Kojima H, Hori M, Nara N, Komeno T, Hasegawa Y, et al. Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol. 1999;27(2):259–65. https://doi.org/10.1016/s0301-472x(98)00041-1 .
doi: 10.1016/s0301-472x(98)00041-1
pubmed: 10029165
Welte K. G-CSF: filgrastim, lenograstim and biosimilars. Expert Opin Biol Ther. 2014;14(7):983–93. https://doi.org/10.1517/14712598.2014.905537 .
doi: 10.1517/14712598.2014.905537
pubmed: 24707817
Welte K, Bonilla MA, Gillio AP, Boone TC, Potter GK, Gabrilove JL, et al. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med. 1987;165(4):941–8. https://doi.org/10.1084/jem.165.4.941 .
doi: 10.1084/jem.165.4.941
pubmed: 3494094
Lever JR, Fergason-Cantrell EA. Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax). Pharmacol Res. 2019;142:87–100. https://doi.org/10.1016/j.phrs.2019.01.040 .
doi: 10.1016/j.phrs.2019.01.040
pubmed: 30721730
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–29. https://doi.org/10.1056/NEJMoa2012971 .
doi: 10.1056/NEJMoa2012971
pubmed: 32786187
Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58(9):1–17. https://doi.org/10.1080/10428194.2017.1283032 .
doi: 10.1080/10428194.2017.1283032
pubmed: 28140720
Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4(9):1074–87. https://doi.org/10.1158/2159-8290.Cd-14-0353 .
doi: 10.1158/2159-8290.Cd-14-0353
pubmed: 24994123
Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour EJ, Ferrajoli A, et al. First report of clinical response to venetoclax in early T-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol. 2018. https://doi.org/10.1200/po.18.00127 .
doi: 10.1200/po.18.00127
pubmed: 31080940
pmcid: 6508880
Arora S, Vachhani P, Bachiashvili K, Jamy O. Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2021;62(9):2292–4. https://doi.org/10.1080/10428194.2021.1897807 .
doi: 10.1080/10428194.2021.1897807
pubmed: 33691573
Zhang X, Li J, Jin J, Yu W. Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen. Ann Hematol. 2020;99(2):395–7. https://doi.org/10.1007/s00277-019-03902-9 .
doi: 10.1007/s00277-019-03902-9
pubmed: 31879788
Agarwal S, Gopalakrishnan S, Mensing S, Potluri J, Hayslip J, Kirschbrown W, et al. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: an exposure-response analysis. Hematol Oncol. 2019;37(4):464–73. https://doi.org/10.1002/hon.2646 .
doi: 10.1002/hon.2646
pubmed: 31251400
Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11(6):1440–53. https://doi.org/10.1158/2159-8290.Cd-20-1465 .
doi: 10.1158/2159-8290.Cd-20-1465
pubmed: 33593877
Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;39(2):359–67. https://doi.org/10.1016/j.clinthera.2017.01.003 .
doi: 10.1016/j.clinthera.2017.01.003
pubmed: 28161120
Dong J, Liu SB, Rasheduzzaman JM, Huang CR, Miao LY. Development of physiology based pharmacokinetic model to predict the drug interactions of voriconazole and venetoclax. Pharm Res. 2022;39(8):1921–33. https://doi.org/10.1007/s11095-022-03289-9 .
doi: 10.1007/s11095-022-03289-9
pubmed: 35725843